The patents cover oral formulations of leading injectables, like bevacizumab (Avastin), trastuzumab (Herceptin), adalimumab (Humira, etanercept (Enbrel), insulin glargine (Lantus), and many others.

In addition, Access rebranded its Cobalamin-mediated oral drug delivery technology as CobOral delivery technology.

Recently, Access Pharma has signed a pre-licensing agreement with a biotechnology company to develop an oral formulation of its currently-marketed, proprietary injectable drug for diabetes.

Access Pharma president and CEO Jeffrey Davis said that the CobOral branding and additional patent filings reflect the high level of interest from partners in CobOral and CobaCyte drug delivery platforms.